Abstract
Peptides have a great potential for the treatment of neurological disorders, but the clinical translation is still facing significant hurdles. Delivery issues are among them: for example the short systemic half-life of peptides, poor passage across the blood brain barrier, slow diffusion through the extracellular space and rapid cerebrospinal fluid washout. This review will discuss new findings on the blood brain barrier and the physiology of the cerebrospinal fluid system, which may be relevant for the delivery of peptides to the brain. It will also discuss delivery issues and opportunities related to different administration routes, i.e. intravenous, intraventricular and intracerebral. Lastly, we summarize stem cell-based approaches; such cell therapy relies on the secretion of soluble factors, i.e. peptides. We highlight approaches to use encapsulated, genetically engineered cells as a vehicle for sustained delivery of peptides to the diseased brain.
Keywords: Blood brain barrier, brain, cerebrospinal fluid, neurological disorder, peptide delivery.
Current Medicinal Chemistry
Title:A Translational View of Peptide Treatment of Neurological Disorders
Volume: 21 Issue: 23
Author(s): Thomas Brinker and Heather Spader
Affiliation:
Keywords: Blood brain barrier, brain, cerebrospinal fluid, neurological disorder, peptide delivery.
Abstract: Peptides have a great potential for the treatment of neurological disorders, but the clinical translation is still facing significant hurdles. Delivery issues are among them: for example the short systemic half-life of peptides, poor passage across the blood brain barrier, slow diffusion through the extracellular space and rapid cerebrospinal fluid washout. This review will discuss new findings on the blood brain barrier and the physiology of the cerebrospinal fluid system, which may be relevant for the delivery of peptides to the brain. It will also discuss delivery issues and opportunities related to different administration routes, i.e. intravenous, intraventricular and intracerebral. Lastly, we summarize stem cell-based approaches; such cell therapy relies on the secretion of soluble factors, i.e. peptides. We highlight approaches to use encapsulated, genetically engineered cells as a vehicle for sustained delivery of peptides to the diseased brain.
Export Options
About this article
Cite this article as:
Brinker Thomas and Spader Heather, A Translational View of Peptide Treatment of Neurological Disorders, Current Medicinal Chemistry 2014; 21 (23) . https://dx.doi.org/10.2174/0929867321666140217124349
DOI https://dx.doi.org/10.2174/0929867321666140217124349 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanism of Action of Flavonoids in Prevention of Inflammation- Associated Skin Cancer
Current Medicinal Chemistry Endothelins Role in the Control of the Acute Phase of Trypanosoma cruzi Infection
Mini-Reviews in Medicinal Chemistry Pharmacologic Therapy In Traumatic Brain Injury: Update On Experimental Treatment Strategies
Current Pharmaceutical Design Glaucoma Pathogenesis and Neurotrophins: Focus on the Molecular and Genetic Basis for Therapeutic Prospects
Current Neuropharmacology Regulation of Endothelial Nitric Oxide Synthase in Pathophysiological Conditions
Cardiovascular & Hematological Disorders-Drug Targets Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Carnitine Metabolism and Deficit - When Supplementation is Necessary?
Current Pharmaceutical Biotechnology Topical Analgesics in Neuropathic Pain
Current Pharmaceutical Design A Nanotechnological Approach to the Management of Alzheimer Disease and Type 2 Diabetes
CNS & Neurological Disorders - Drug Targets A Review of Pharmacological and Phytochemical Studies on Convolvulaceae Species <i>Rivea</i> and <i>Ipomea</i>
Current Traditional Medicine Viral Encephalitis: Current Treatments and Future Perspectives
Central Nervous System Agents in Medicinal Chemistry Update on Pharmacologic Retinal Vascular Toxicity
Current Pharmaceutical Design Signs and Related Mechanisms of Ethanol Hepatotoxicity
Current Drug Abuse Reviews Anti-Angiogenic Treatment for Exudative Age-Related Macular Degeneration: New Strategies are Underway
Current Angiogenesis (Discontinued) Morphofunctional Aspects of the Blood-Brain Barrier
Current Drug Metabolism Central Administration of Neuropeptide FF and Related Peptides Attenuate Systemic Morphine Analgesia in Mice
Protein & Peptide Letters Medicinal Chemistry and Anti-Inflammatory Activity of Nitric Oxide-Releasing NSAI Drugs
Mini-Reviews in Medicinal Chemistry Anesthesia for Bronchoscopy
Current Pharmaceutical Design Pericyte Loss in Diabetic Retinopathy: Mechanisms and Consequences
Current Medicinal Chemistry Combination of Therapeutic Hypothermia and Other Neuroprotective Strategies after An Ischemic Cerebral Insult
Current Neuropharmacology